Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Department of Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
BJU Int. 2019 Sep;124(3):418-423. doi: 10.1111/bju.14704. Epub 2019 Mar 4.
To determine if the presence of non-urothelial variant histology (NUVH) is associated with a poorer prognosis following radical cystectomy (RC) compared to pure urothelial carcinoma (PUC).
A prospectively maintained database of all patients undergoing RC at a high-volume regional tertiary bladder cancer service between January 2010 and January 2017 was retrospectively analysed looking for patients with NUVH. Multivariate Cox proportional hazards regression analysis was used to determine disease recurrence, overall survival and bladder cancer-specific survival, as well as lymph node positivity. Association of tumour stage was determined using chi-squared analysis.
In total, 430 patients underwent RC of which 73 (17%) had NUVH and 357 (83%) had PUC. The median (range) follow-up was 45.0 (8.5-100.2) months. The presence of NUVH was associated with both increased overall (hazard ratio [HR] 1.86, 95% confidence interval [CI] 1.21-2.85) and bladder cancer-specific mortality (HR 1.81, 95% CI 1.91-3.01), as well as disease recurrence (HR 1.71, 95% CI 1.06-2.75) in multivariate analysis. Squamous cell variant was also associated with increased overall mortality (HR 1.91, 95% CI 1.16-3.13), cancer-specific mortality (HR 2.03, 95% CI 1.21-3.42) and disease recurrence (HR 2.08, 95% CI 1.23-3.52), although this was not seen in other variant subtypes. Lymph node positivity was not associated with NUVH in multivariate analysis (HR 1.28, 95% CI 0.59-2.75), but NUVH was associated with advanced tumour stage on chi-squared analysis (P < 0.001).
Our results showed a risk of shorter survival in NUVH compared to PUC. This suggests NUVH as an independent predictor of worse outcomes. As a result, patients with NUVH should be counselled preoperatively that overall and disease-specific outcomes are worse postoperatively and about the possible need for adjuvant treatment.
确定根治性膀胱切除术(RC)后非尿路上皮变异组织学(NUVH)的存在是否与纯尿路上皮癌(PUC)相比预后更差。
回顾性分析 2010 年 1 月至 2017 年 1 月在高容量区域性三级膀胱癌服务机构接受 RC 的所有患者的前瞻性维护数据库,寻找具有 NUVH 的患者。使用多变量 Cox 比例风险回归分析确定疾病复发、总生存和膀胱癌特异性生存,以及淋巴结阳性。使用卡方分析确定肿瘤分期的关联。
共 430 例患者接受 RC,其中 73 例(17%)有 NUVH,357 例(83%)有 PUC。中位(范围)随访时间为 45.0(8.5-100.2)个月。NUVH 的存在与总生存(风险比 [HR] 1.86,95%置信区间 [CI] 1.21-2.85)和膀胱癌特异性死亡率(HR 1.81,95% CI 1.91-3.01)以及疾病复发(HR 1.71,95% CI 1.06-2.75)显著相关。鳞状细胞变异也与总死亡率(HR 1.91,95% CI 1.16-3.13)、癌症特异性死亡率(HR 2.03,95% CI 1.21-3.42)和疾病复发(HR 2.08,95% CI 1.23-3.52)相关,尽管在其他变异亚型中未见这种情况。多变量分析中,淋巴结阳性与 NUVH 无关(HR 1.28,95% CI 0.59-2.75),但 NUVH 与卡方分析中的晚期肿瘤分期相关(P<0.001)。
与 PUC 相比,我们的结果显示 NUVH 存在生存风险较短。这表明 NUVH 是预后更差的独立预测因素。因此,应在术前告知 NUVH 患者,术后总体和疾病特异性结局较差,并且可能需要辅助治疗。